Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Capitol Capsule: Paying For Precision Medicine: The Coverage Conundrum

This article was originally published in Scrip

Executive Summary

While the science of personalized medicine has been moving at an extremely rapid pace in recent years – evidenced by the fact that 20% of the novel therapies approved by the FDA in 2014 were targeted therapies – the efforts by the biopharmaceutical industry and others in the biomedical community, including the National Institutes of Health (NIH), will all be for naught if payers don't catch up, leaving patients without access, a panel of stakeholders said last week in Washington.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts